source
- Acting FDA commissioner reports strong public interest in new expedited IND pilotActing FDA Commissioner Kyle Diamantas told attendees at the Friends of Cancer Research annual meeting that the agency’s newly launched Expedited IND pilot has attracted considerable public attenti…
- AbCellera halts development of OX40 antibody ABCL575 after phase-1 trialAbCellera announced it will not move ABCL575 beyond phase 1, ending its OX40 program. The phase-1 study met its endpoints, showing a favorable tolerability profile and pharmacokinetics that suppor…